ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO507

Does Single-Dose Conjugated Pneumococcal Vaccine Provide Enough Antibody Response in Peritoneal Dialysis Patients?

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Eren, Necmi, Kocaeli University, Kocaeli, Turkey
  • Albayrak, Hayrunnisa, Kocaeli University, Kocaeli, Turkey
  • Bek, Sibel, Kocaeli University School of Medicine, Kocaeli, Turkey
Background

Dialysis patients have 10-100 fold-increased risk of sepsis and pneumonia related mortality.The incidence of pneumonia increased and over half of reported pneumonia cases in dialysis patients are caused by Streptococcus pneumonia. Immunization against infectious diseases is a fairly simple, prevention strategy in dialysis patients. Implementation of polysacharidde pneumococcal vaccination (PPSV23) has led to an considerable decrease in pneumonia incidence. In accordance to PPSV23, conjugated pneumococcal vaccine (PCV13) has an increased and sustainable immunogenic response. In dialysis patients, antibody response to vaccination is decreased. This is the first study that investigates whether PCV13 vaccination provides enough antibody response in peritoneal dialysis (PD) patients.

Methods

Participants received a single dose of 0.5 ml of PCV13 administered intramuscularly. Blood samples were drawn prior to vaccination and at 1 month after vaccination. Serum antipneumoccal antibody level is measured by ELISA method.

Results

69 PD (39 male, 30 female) patients and 10 healthy volunteers were inrolled in our study. Mean age was 52,6 ± 12,9 years (Image 1). In PD patients and control groups, first month antibody levels were increased statistically significant than prevaccination ( p=0,001, p=0,008, respectively). First month antibody levels were higher in control group compared to patients (p=0,013). In PD group, statistically significant relationship were observed between antibody levels and serum albumin, CRP, Kt/V, weekly CrCl, nPCR parameters (Image 2).

Conclusion

In PD patients, PCV13 vaccination resulted enough but lower antibody levels than control group. Malnutrition, inflammation and lower dialysis adequacy were associated with lower antibody response.